Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia.
Quality of life (QL) was evaluated in 101 patients with AML undergoing intensive and prolonged treatment at 12 sequential time points by using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C 30 questionnaire and the profile of mood states scale (POMS). For those patients having completed the course of inpatient treatment (n=37), QL improved from the beginning of chemotherapy to the end of inpatient treatment. Patients who subsequently went off protocol did not differ significantly in their self-assessed QL when compared with patients who completed therapy. Fatigue was more closely related to QL than nausea/emesis or appetite loss, but did not correlate with hemoglobin levels.
Schumacher
Andrea
A
Department of Medicine/Hematology and Oncology, University of Münster, Germany. anschum@uni-muenster.de
Wewers
Dieter
D
Heinecke
Achim
A
Sauerland
Cristina
C
Koch
Olaf M
OM
van de Loo
Jürgen
J
Büchner
Thomas
T
Berdel
Wolfgang E
WE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005221:Fatigue / Q000139:chemically induced / Q000209:etiology; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents